Why Your Peptide Isn’t Working: The Foundation Every Protocol Skips | Dr. Greg Jones

Most peptide protocols aren't failing because the peptide is wrong. They're failing because nobody built the foundation for the signal to land.

Dr. Greg Jones spent two decades as a Navy nuclear engineer before an unfulfilling stretch after retirement pushed him toward medicine. He initially aimed for pharmacy school after losing his mother to cancer, pivoted to naturopathic medicine, then moved from regenerative injection therapy into peptides after noticing his healthiest patients needed one injection while his metabolically unwell patients needed a series. He now runs Enovative Wellness Center in Phoenix, applying what he calls health engineering to the body. He grounds peptide therapy in plain terms: a peptide is a sequence of amino acids that signals a specific cell rather than broadcasting an effect across the whole body, and that precision is exactly why peptides underperform when inflammation, poor sleep, oxidative stress, or metabolic dysfunction haven't been addressed first.

Dr. Jones and Dr. Crawford compare specific protocols: BPC-157 versus TB-500 and full thymosin beta-4, MOTS-c versus SS-31 for mitochondrial support, and growth hormone secretagogues, which Dr. Jones supports for most adults over 40 with real exceptions for active malignancy, pituitary damage, and uncontrolled insulin resistance. They also debate how closely to monitor IGF-1, and Dr. Crawford shares how he dose-adjusts peptides for pediatric and complex neurological cases. The conversation closes on the FDA Pharmacy Compounding Advisory Committee's recent vote recommending six of seven peptides for continued compounding access, and why Dr. Jones believes restricting that access pushes patients toward an unregulated gray market rather than away from risk.

Key Takeaways

Here's what stood out from Dr. Jones and Dr. Crawford's conversation:

• A Signal, Not a Drug: Dr. Jones explains that peptides work by binding receptors and telling a specific cell what to do, unlike medications that broadcast an effect throughout the body.
• Fix the Foundation First: Peptides underperform in patients with unresolved inflammation, poor sleep, or metabolic dysfunction, since the foundation determines how well the signal is received.
• BPC-157 vs. TB-500: Dr. Jones prefers full thymosin beta-4 over the TB-500 fragment for its broader immune and cardiovascular benefits, while BPC-157 remains his go-to for gut health and recovery.
• Growth Hormone After 40, With Caveats: Dr. Jones generally supports growth hormone secretagogues for adults over 40, but avoids them in patients with active malignancy, pituitary damage, or uncontrolled insulin resistance.
• The IGF-1 Debate: Both doctors monitor IGF-1 periodically, watching for values that climb excessively high rather than reacting to normal, expected increases.
• Peptides in Pediatric Cases: Dr. Crawford dose-adjusts peptides like BPC-157 and thymosin alpha-1 for younger and more complex neurological patients, starting low and titrating slowly.
• The FDA Vote & the Gray Market: The FDA's compounding advisory committee recommended six of seven peptides for continued access, and Dr. Jones argues that restricting compounding pushes patients toward unregulated, unaccountable sources instead of away from risk.

Disclaimer

This episode is for educational purposes only and is not medical advice. The peptides, dosages, and protocols discussed, including off-label, compounded, and pediatric use, are not a recommendation to self-diagnose, self-source, or self-dose. Always consult a licensed physician before starting, changing, or stopping any peptide, hormone, or medical protocol.

Share the Love

Never miss an episode by subscribing via Apple Podcasts, Spotify, Amazon Music, or by RSS!